peginesatide

11/01/2010 - "This article discusses unmet needs in the management of anemia of CKD, presents peginesatide attributes, reviews the results of select peginesatide clinical studies, and discusses the potential value of peginesatide as an alternative anemia management option."
03/01/2014 - "It seems that peginesatide would not become a new approach for treating anemia of CKD patients, but rather a falling star. "
10/01/2013 - "On peginesatide and anemia treatment in CKD."
07/01/2013 - "Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?"
05/01/2013 - "Peginesatide for the treatment of renal disease-induced anemia."

01/24/2013 - "However, cardiovascular events and mortality were increased with peginesatide in patients with chronic kidney disease who were not undergoing dialysis. "
01/01/2013 - "A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis."
07/01/2011 - "Clinical use of peginesatide is anticipated to result in chronic dosing in chronic kidney disease (CKD) patients, and the nonclinical data to support development should include an evaluation of carcinogenic potential evaluation. "
07/01/2015 - "The purpose of the present study was to assess, for the first time, the efficacy and safety of peginesatide in chronic kidney disease (CKD) patients receiving peritoneal dialysis (PD) and previously on epoetin treatment. "
11/01/2011 - "Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients."

01/24/2013 - "In two randomized, controlled, open-label studies (PEARL 1 and 2), patients received peginesatide once a month, at a starting dose of 0.025 mg or 0.04 mg per kilogram of body weight, or darbepoetin once every 2 weeks, at a starting dose of 0.75 μg per kilogram. "
11/01/2011 - "Chronic kidney disease patients who were not on dialysis and not receiving treatment with erythropoiesis-stimulating agents in the 12 weeks before study drug administration were sequentially assigned to one of 10 cohorts; cohorts differed in starting peginesatide dose (different body weight-based or absolute doses), route of administration (intravenous or subcutaneous), and frequency of administration (every 4 or 2 weeks). "

11/01/2012 - "ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. "

11/01/2012 - "ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. "